Stocks in the Spotlight: McDonald’s Corporation (MCD), The Hartford Financial Services Group, Inc. (HIG), Allergan plc (AGN)

McDonald’s Corporation (MCD) had a light trading with around 3.01M shares changing hands compared to its three month average trading volume of 3.69M. The stock traded between $126.31 and $127.82 before closing at the price of $126.7 with 0.17% change on the day. The Oak Brook Illinois 60523 based company is currently trading 15.73% above its 52 week low of $110.33 and -1.77% below its 52 week high of $131.96. Both the RSI indicator and target price of 71.68 and $131.17 respectively, lead us to believe that it could drop over the coming weeks.

McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages. As of December 31, 2015, it operated 36,525 restaurants, including 30,081 franchised restaurants comprising 21,147 franchised to conventional franchisees, 5,529 licensed to developmental licensees, and 3,405 licensed to foreign affiliates; and 6,444 company-operated restaurants. The company has strategic partnerships with CITIC Limited, CITIC Capital, and The Carlyle Group to expand its business in Mainland China and Hong Kong. McDonald’s Corporation was founded in 1940 and is based in Oak Brook, Illinois.

The Hartford Financial Services Group, Inc. (HIG) managed to rebound with the stock declining 0% or $0 to close the day at $48.6 on active trading volume of 3M shares, compared to its three month average trading volume of 2.5M. The Hartford Connecticut 06155 based company has been outperforming the property & casualty insurance group over the past 52 weeks, with the stock gaining 18.65%, compared to the industry which has advanced 27.04% over the same period. With RSI of 56.97, the stock should still continue to rise and get closer to its one year target estimate of $52.42, making it a hold for now.

The Hartford Financial Services Group, Inc., through its subsidiaries, provides insurance and financial services to individual and business customers in the United States. It operates through six segments: Commercial Lines, Personal Lines, Property & Casualty Other Operations, Group Benefits, Mutual Funds, and Talcott Resolution. The Commercial Lines segment offers workers’ compensation, property, automobile, liability, umbrella, marine, and livestock insurance, as well as customized insurance products and services, including general liability, professional liability, bond, and specialty casualty coverages. The Personal Lines segment provides automobile, homeowners, and personal umbrella coverages to individuals. The Property & Casualty Other Operations segment manages property and casualty insurance. The Group Benefits segment offers group life, accident and disability coverage, and group retiree health to employer groups, associations, and affinity groups; and disability underwriting, administration, claims processing, and reinsurance to other insurers and self-funded employer plans. The Mutual Funds segment provides investment products for retail and retirement accounts; and investment-management and administrative services, such as product design, implementation, and oversight, as well as the runoff of the mutual funds supporting the company’s variable annuity products. The Talcott Resolution segment engages in the U.S. annuity, institutional, and private-placement life insurance businesses. It has a research partnership with UCLA Anderson Forecast to understand the critical economic issue and other trends affecting small business. The Hartford Financial Services Group, Inc. was founded in 1810 and is headquartered in Hartford, Connecticut.

Allergan plc (AGN) shares were down in last trading by -0.96% to $246.93. It experienced lighter than average volume on day. The stock increased in value by almost 0.51% over the past week and grew 14.02% in the past month. It is currently trading 15.82% above its 50 day moving average and 8.92% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -18.05% decrease in value from its one year high of $301.32. The RSI indicator value of 78.81, lead us to believe that it may reverse gains in the near term.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Further, the company develops, processes, and markets tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgical procedures to repair soft tissue defects. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

 

Momentum Stocks: Continental Resources, Inc. (CLR), Allergan plc (AGN), Autodesk, Inc. (ADSK)

Continental Resources, Inc. (CLR) grew with the stock adding 1.16% or $0.54 to close at $46.97 on light trading volume of 1.94M compared its three months average trading volume of 2.74M. The Oklahoma City Oklahoma 73102 based company operating under the Independent Oil & Gas industry has been trending up for the last 52 weeks, with the shares price now 154.44% up for the period and down by -8.87% so far this year. With price target of $60.94 and a 177.6% rebound from 52-week low, Continental Resources, Inc. has plenty of upside potential, making it a hold with a view buy.

Continental Resources, Inc. explores for, develops, and produces crude oil and natural gas properties in the north, south, and east regions of the United States. The company sells its crude oil and natural gas production to energy marketing companies, crude oil refining companies, and natural gas gathering and processing companies. As of December 31, 2015, its estimated proved reserves were 1,226 million barrels of crude oil equivalent (MMBoe) with estimated proved developed reserves of 525 MMBoe. Continental Resources, Inc. was founded in 1967 and is based in Oklahoma City, Oklahoma.

Allergan plc (AGN) had a light trading with around 2.63M shares changing hands compared to its three month average trading volume of 4.53M. The stock traded between $244.65 and $249.27 before closing at the price of $248.57 with 0.73% change on the day. The Dublin Dublin D17 E400 based company is currently trading 34.73% above its 52 week low of $184.5 and -17.51% below its 52 week high of $301.32. Both the RSI indicator and target price of  and $263.37 respectively, lead us to believe that it could rise over the coming weeks.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Further, the company develops, processes, and markets tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgical procedures to repair soft tissue defects. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Autodesk, Inc. (ADSK) saw its value increase by 0.31% as the stock gained $0.26 to finish the day at a closing price of $84.54. The stock was higher in trading and has fluctuated between $45.34-$85.11 per share for the past year. The shares, which traded within a range of $82.81 to $84.59 during the day, are up by 14.54% in the past three months and up by 34.23% over the past six months. It is currently trading 2.96% above its 20 day moving average and 6.93% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $81.71 a share over the next twelve months. The current relative strength index (RSI) reading is 61.18.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Autodesk, Inc. operates as a design software and services company worldwide. The company’s Architecture, Engineering and Construction segment offers Autodesk Building Design Suites to manage various phases of design and construction; Autodesk Revit products that offer model-based design and documentation systems; Autodesk Infrastructure Design Suites; AutoCAD Civil 3D, a surveying, design, analysis, and documentation solution; and AutoCAD Map 3D software for infrastructure planning, design, and management. Its Platform Solutions and Emerging Business segment offers AutoCAD software, a professional design, drafting, detailing, and visualization software; and AutoCAD LT, a professional drafting and detailing software. The company’s Manufacturing segment provides Autodesk Product Design Suites for digital prototyping; Autodesk Inventor to go beyond 3D design to digital prototyping; AutoCAD Mechanical software to accelerate the mechanical design process; Autodesk Moldflow, an injection molding simulation software; Autodesk Delcam, a CAD and computer-aided manufacturing software; Autodesk PLM 360, a product lifecycle management application; and Autodesk Fusion 360, a product development environment. Its Media and Entertainment segment offers Autodesk Maya and Autodesk 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and Autodesk Flame and Autodesk Lustre software applications that offer editing, finishing, and visual effects design and color grading solutions. Autodesk, Inc. sells consumer products for digital art, personal design and creativity, and home design in digital storefronts and over the Internet. It licenses or sells its products to customers in the architecture, engineering, and construction; manufacturing; and digital media, consumer, and entertainment industries directly, as well as through resellers and distributors. Autodesk, Inc. was founded in 1982 and is headquartered in San Rafael, California.

 

Stocks Trend Analysis: Allergan plc (AGN), The Goldman Sachs Group, Inc. (GS), salesforce.com, inc. (CRM)

Allergan plc (AGN) continued its upward trend with the stock climbing 0.28% or $0.68 to close the day at $246.36 on light trading volume of 3.08M shares, compared to its three month average trading volume of 4.7M. The Dublin Dublin D17 E400 based company has been underperforming the drugs – generic group over the past 52 weeks, with the stock losing -10.27%, compared to the industry which has advanced 0.11% over the same period. With RSI of 82.83, the stock should still continue to rise and get closer to its one year target estimate of $263.37, making it a hold for now.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Further, the company develops, processes, and markets tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgical procedures to repair soft tissue defects. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

The Goldman Sachs Group, Inc. (GS) grew with the stock adding 0.48% or $1.17 to close at $242.72 on light trading volume of 3.07M compared its three months average trading volume of 4.43M. The New York New York 10282 based company operating under the Investment Brokerage – National industry has been trending up for the last 52 weeks, with the shares price now 75.2% up for the period and up by 1.37% so far this year. With price target of $247.8 and a 77.27% rebound from 52-week low, The Goldman Sachs Group, Inc. has plenty of upside potential, making it a hold with a view buy.

The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment management company worldwide. It operates through four segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Management. The Investment Banking segment provides financial advisory services, such as strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, spin-offs, and risk management; and underwriting services, including public offerings and private placements of various securities and other financial instruments, as well as derivative transactions entered into with public and private sector clients. The Institutional Client Services segment is involved in client execution activities related to making markets in interest rate products, credit products, mortgages, currencies, commodities, and equities; and provides securities services, such as financing, securities lending, and other prime brokerage services, as well as markets in and clears client transactions on primary stock, options, and futures exchanges. The Investing & Lending segment invests in and originates longer-term loans to provide financing to clients; and makes investments in debt securities and loans, public and private equity securities, and real estate entities. The Investment Management segment offers investment management products and services; and wealth advisory services, including portfolio management and financial counseling, and brokerage and other transaction services. The company serves corporations, financial institutions, governments, and individuals. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

salesforce.com, inc. (CRM) failed to extend gains with the stock declining -0.48% or $-0.39 to close the day at $80.64 on lower than average trading volume of 3.06M shares, compared to its three month average trading volume of 5.97M. The San Francisco California 94105 based company has been outperforming the application software companies by 6.1888% for last three months and its recent gains have pushed the stock slightly up 17.79% YTD, versus the application software industry which is up 9.18% for the same period. The RSI of 72.43 indicates the stock is overbought at the current levels, sell for now.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. It offers enterprise cloud computing applications and platform services, including Sales Cloud that enables companies to store data, monitor leads and progress, forecast opportunities, gain insights through relationship intelligence, and collaborate around sales on desktop and mobile devices. The company also provides Service Cloud that enables companies to deliver personalized customer service and support, as well as connects their service agents with customers on various devices; and Marketing Cloud, which enables companies to plan, personalize, and optimize customer interactions. In addition, it offers Community Cloud that enables companies to engage with groups of people by giving them access to information, applications, and experts; Analytics Cloud, an application, which enables companies to deploy sales, service, marketing, and custom analytics applications using various data source; Internet of Things Cloud that enables customers to process data, as well as build personalized actions and engage with customers in real time; and App Cloud, an application development platform for companies to deliver connected applications for various business needs. Further, the company provides professional services, including consulting, deployment, training, and design and integration services to facilitate the adoption of its cloud solutions, as well as offers various education service offerings ranging from introductory online courses to advanced architecture certifications. It sells and markets services primarily through its direct sales force, as well as through consulting firms, systems integrators, and regional partners. The company has a strategic alliance with Cisco to develop IoT and contact center platforms. salesforce.com, inc. was founded in 1999 and is headquartered in San Francisco, California.

 

Stocks Intraday Alert: Abbott Laboratories (ABT), First Data Corporation (FDC), Allergan plc (AGN)

Abbott Laboratories (ABT) failed to extend gains with the stock declining -1.14% or $-0.49 to close the day at $42.4 on lower than average trading volume of 6.72M shares, compared to its three month average trading volume of 9.45M. The Abbott Park Illinois 60064 based company has been outperforming the medical appliances & equipment companies by 7.0382% for last three months and its recent gains have pushed the stock slightly up 11.1% YTD, versus the medical appliances & equipment industry which is up 6.52% for the same period. The RSI of 67.14 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

First Data Corporation (FDC) had a active trading with around 6.6M shares changing hands compared to its three month average trading volume of 3.99M. The stock traded between $15.02 and $15.45 before closing at the price of $15.15 with -2.26% change on the day. The Atlanta Georgia 30342 based company is currently trading 81% above its 52 week low of $8.37 and -5.96% below its 52 week high of $16.11. Both the RSI indicator and target price of 46.63 and $17.25 respectively, lead us to believe that it should be put on hold over the coming weeks.

First Data Corporation provides electronic commerce solutions for merchants, financial institutions, and card issuers worldwide. It operates through three segments: Global Business Solutions, Global Financial Solutions, and Network & Security Solutions. The Global Business Solutions segment offers retail point-of-sale merchant acquiring and e-commerce services; and next-generation offerings, such as mobile payment services and webstore-in-a-box solutions, as well as its cloud-based Clover point-of-sale operating system, which includes a marketplace for proprietary and third-party business applications. The Global Financial Solutions segment provides credit solutions for bank and non-bank issuers, including credit and retail private-label card processing solutions; and licensed financial software systems, such as VisionPLUS bank processing application and lending solutions. This segment also offers a suite of related services, including card personalization and embossing, statement printing, client service, and remittance processing services to financial institutions. The Network & Security Solutions segment provides various value-added solutions, which include electronic funds transfer network solutions, such as debit card processing solutions; stored value network solutions; and security and fraud management solutions. This segment also supports its online and mobile banking digital strategies, and its business supporting mobile wallets. First Data Corporation was founded in 1989 and is headquartered in Atlanta, Georgia.

Allergan plc (AGN) traded within a range of $231.53 to $243.8 after opening the day at $236.09. The company has seen its stock increase in value by 14.84% so far this year. The stock was up close to 3.68% on active volume in last trading session and closed at $241.17 per share. After the recent gain, the stock is currently holding -19.96% below its 52 week high of $301.32 and 30.72% above its 12-month low of $184.5. The shares are up by over 20.92% in the last three months, and the RSI indicator value of 80.18 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

 

3 Trending Stocks: BB&T Corporation (BBT), Allergan plc (AGN), Anadarko Petroleum Corporation (APC)

BB&T Corporation (BBT) failed to extend gains with the stock declining -0.39% or $-0.18 to close the day at $46.43 on light trading volume of 3.19M shares, compared to its three month average trading volume of 5.38M. The Winston-Salem North Carolina 27101 based company has been outperforming the regional – southeast banks group over the past 52 weeks, with the stock gaining 49.58%, compared to the industry which has advanced 57.99% over the same period. With RSI of 51.03, the stock should still continue to rise and get closer to its one year target estimate of $48.52, making it a hold for now.

BB&T Corporation operates as a financial holding company that provides various banking and trust services for retail and commercial clients. It operates in six segments: Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Services, and Financial Services. The company’s deposit products include noninterest-bearing checking, interest-bearing checking, savings, and money market deposit accounts, as well as certificates of deposit and individual retirement accounts. Its loan portfolio comprises commercial, financial and agricultural, real estate construction and land development, real estate mortgage, and consumer loans. The company also provides asset management, automobile lending, bankcard lending, consumer finance, home equity and mortgage lending, insurance, investment brokerage, mobile/online banking, payment, sales finance, small business lending, and wealth management/private banking services. In addition, it offers association, capital markets, institutional trust, insurance premium finance, international banking, leasing, merchant, mortgage warehouse lending, private equity investments, real estate lending, and supply chain management services. Further, the company provides retail brokerage, equity and debt underwriting, investment advice, corporate finance, and equity research services, as well as facilitates the origination, trading, and distribution of fixed-income securities and equity products. As of April 4, 2016, it operated approximately 2,265 financial centers in 15 states and Washington, D.C. The company was founded in 1872 and is headquartered in Winston-Salem, North Carolina.

Allergan plc (AGN) climbed 1.54% during last trading as the stock added $3.56 to finish the day at $234.43 with about 3.17M shares changing hands, compared to its three month average trading volume of 4.8M. The $92.06B market cap company, which fluctuated between $227 and $234.58 during the day, currently situated 27.06% above its 52 week low of $184.5 and -22.2% away from its one year high of $301.32. The RSI of 78.28 indicates the stock is overbought at the current levels, sell for now.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Anadarko Petroleum Corporation (APC) saw its value decrease by -1.85% as the stock dropped $-1.3 to finish the day at a closing price of $69.1. The stock was lighter in trading and has fluctuated between $33.85-$73.33 per share for the past year. The shares, which traded within a range of $68.78 to $70.87 during the day, are up by 14.77% in the past three months and up by 31.15% over the past six months. It is currently trading -1.67% below its 20 day moving average and -0.65% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $81.94 a share over the next twelve months. The current relative strength index (RSI) reading is 46.63. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Anadarko Petroleum Corporation engages in the exploration, development, production, and marketing of oil and gas properties. It operates through three segments: Oil and Gas Exploration and Production; Midstream; and Marketing. The Oil and Gas Exploration and Production segment explores for and produces oil, condensate, natural gas, and natural gas liquids (NGLs). The Midstream segment provides gathering, processing, treating, and transportation services to Anadarko and third-party oil, natural-gas, and NGLs producers, as well as owns and operates gathering, processing, treating, and transportation systems in the United States. The Marketing segment markets oil, natural gas, and NGLs in the United States; oil and NGLs internationally; and anticipated liquefied natural gas production from Mozambique. The company’s asset portfolio includes U.S. onshore resource plays in the Rocky Mountains area, the southern United States, the Appalachian basin, and Alaska; the deepwater Gulf of Mexico; and in Algeria, Ghana, Mozambique, Colombia, Côte d’Ivoire, New Zealand, Kenya, and other countries. As of December 31, 2015, it had approximately 2.1 billion barrels of oil equivalent of proved reserves. Anadarko Petroleum Corporation was founded in 1959 and is headquartered in The Woodlands, Texas.

 

Stocks on Trader’s Radar: Costco Wholesale Corporation (COST), Weyerhaeuser Co. (WY), Allergan plc (AGN)

Costco Wholesale Corporation (COST) managed to rebound with the stock climbing 3.89% or $6.29 to close the day at $168.15 on active trading volume of 5.81M shares, compared to its three month average trading volume of 2.19M. The Issaquah Washington 98027 based company has been outperforming the discount, variety stores group over the past 52 weeks, with the stock gaining 15.94%, compared to the industry which has advanced 4.67% over the same period. With RSI of 68, the stock should still continue to rise and get closer to its one year target estimate of $174.8, making it a hold for now.

Costco Wholesale Corporation, together with its subsidiaries, operates membership warehouses. It offers branded and private-label products in a range of merchandise categories. The company provides dry and packaged foods, and groceries; snack foods, candies, alcoholic and nonalcoholic beverages, and cleaning supplies; appliances, electronics, health and beauty aids, hardware, and garden and patio; meat, bakery, deli, and produces; and apparel and small appliances. It also operates gas stations, pharmacies, optical dispensing centers, food courts, and hearing-aid centers; and engages in the travel businesses. In addition, the company provides gold star individual and business membership services. As of August 28, 2016, it operated 715 warehouses, including 501 warehouses in the United States, Washington, District of Columbia, and Puerto Rico; 91 in Canada; 36 in Mexico; 28 in the United Kingdom; 25 in Japan; 12 in Korea; 12 in Taiwan; 8 in Australia; and 2 in Spain. Further, the company sells its products through online. The company was formerly known as Costco Companies, Inc. Costco Wholesale Corporation was founded in 1976 and is based in Issaquah, Washington.

Weyerhaeuser Co. (WY) climbed 1.06% during last trading as the stock added $0.33 to finish the day at $31.44 with about 5.67M shares changing hands, compared to its three month average trading volume of 4.03M. The $23.52B market cap company, which fluctuated between $30.79 and $31.5 during the day, currently situated 48.5% above its 52 week low of $22.06 and -5.53% away from its one year high of $33.28. The RSI of 55.48 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Weyerhaeuser Co. is a real estate investment trust. It primarily invests in United States. The firm operates under four business segments, timberlands, wood products, cellulose fibers and real estate. It owns timberlands primarily in the U.S and has long-term licenses in Canada. The firm manufactures wood and specialty cellulose fibers products, and develops real estate, primarily as a builder of single-family homes. Weyerhaeuser Co was founded in 1900 and is based in Seattle, Washington.

Allergan plc (AGN) saw its value increase by 0.09% as the stock gained $0.2 to finish the day at a closing price of $229.52. The stock was higher in trading and has fluctuated between $184.5-$301.32 per share for the past year. The shares, which traded within a range of $226.5 to $235.19 during the day, are up by 10% in the past three months and down by -9.11% over the past six months. It is currently trading 5.98% above its 20 day moving average and 12.86% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $260.79 a share over the next twelve months. The current relative strength index (RSI) reading is 75.04. The technical indicator do not lead us to believe the stock will see more gains any time soon.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

 

Investor’s Alert: Anadarko Petroleum Corporation (APC), Autodesk, Inc. (ADSK), Allergan plc (AGN)

Anadarko Petroleum Corporation (APC) managed to rebound with the stock climbing 1.02% or $0.7 to close the day at $69.53 on higher than average trading volume of 5.37M shares, compared to its three month average trading volume of 4.39M. The The Woodlands Texas 77380 based company has been outperforming the independent oil & gas companies by 13.1616% for last three months and its recent gains have offset losses to -0.29% YTD, versus the independent oil & gas industry which is down -2.64% for the same period. The RSI of 46.01 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Anadarko Petroleum Corporation engages in the exploration, development, production, and marketing of oil and gas properties. It operates through three segments: Oil and Gas Exploration and Production; Midstream; and Marketing. The Oil and Gas Exploration and Production segment explores for and produces oil, condensate, natural gas, and natural gas liquids (NGLs). The Midstream segment provides gathering, processing, treating, and transportation services to Anadarko and third-party oil, natural-gas, and NGLs producers, as well as owns and operates gathering, processing, treating, and transportation systems in the United States. The Marketing segment markets oil, natural gas, and NGLs in the United States; oil and NGLs internationally; and anticipated liquefied natural gas production from Mozambique. The company’s asset portfolio includes U.S. onshore resource plays in the Rocky Mountains area, the southern United States, the Appalachian basin, and Alaska; the deepwater Gulf of Mexico; and in Algeria, Ghana, Mozambique, Colombia, Côte d’Ivoire, New Zealand, Kenya, and other countries. As of December 31, 2015, it had approximately 2.1 billion barrels of oil equivalent of proved reserves. Anadarko Petroleum Corporation was founded in 1959 and is headquartered in The Woodlands, Texas.

Autodesk, Inc. (ADSK) had a light trading with around 1.25M shares changing hands compared to its three month average trading volume of 2.38M. The stock traded between $79.8 and $81.35 before closing at the price of $81.34 with 0.22% change on the day. The San Rafael California 94903 based company is currently trading 95.53% above its 52 week low of $41.6 and -3.12% below its 52 week high of $83.96. Both the RSI indicator and target price of 58.95 and $80.94 respectively, lead us to believe that it should be put on hold over the coming weeks.

Autodesk, Inc. operates as a design software and services company worldwide. The company’s Architecture, Engineering and Construction segment offers Autodesk Building Design Suites to manage various phases of design and construction; Autodesk Revit products that offer model-based design and documentation systems; Autodesk Infrastructure Design Suites; AutoCAD Civil 3D, a surveying, design, analysis, and documentation solution; and AutoCAD Map 3D software for infrastructure planning, design, and management. Its Platform Solutions and Emerging Business segment offers AutoCAD software, a professional design, drafting, detailing, and visualization software; and AutoCAD LT, a professional drafting and detailing software. The company’s Manufacturing segment provides Autodesk Product Design Suites for digital prototyping; Autodesk Inventor to go beyond 3D design to digital prototyping; AutoCAD Mechanical software to accelerate the mechanical design process; Autodesk Moldflow, an injection molding simulation software; Autodesk Delcam, a CAD and computer-aided manufacturing software; Autodesk PLM 360, a product lifecycle management application; and Autodesk Fusion 360, a product development environment. Its Media and Entertainment segment offers Autodesk Maya and Autodesk 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and Autodesk Flame and Autodesk Lustre software applications that offer editing, finishing, and visual effects design and color grading solutions. Autodesk, Inc. sells consumer products for digital art, personal design and creativity, and home design in digital storefronts and over the Internet. It licenses or sells its products to customers in the architecture, engineering, and construction; manufacturing; and digital media, consumer, and entertainment industries directly, as well as through resellers and distributors. Autodesk, Inc. was founded in 1982 and is headquartered in San Rafael, California.

Allergan plc (AGN) traded within a range of $209.31 to $219.55 after opening the day at $209.91. The company has seen its stock increase in value by 4.23% so far this year. The stock was up close to 3.31% on light volume in last trading session and closed at $218.89 per share. After the recent gain, the stock is currently holding -27.36% below its 52 week high of $301.32 and 18.64% above its 12-month low of $184.5. The shares are up by over 2.55% in the last three months, and the RSI indicator value of 64.02 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

 

Stocks Roundup: Colgate-Palmolive Company (CL), Allergan plc (AGN), Conagra Brands, Inc. (CAG)

Colgate-Palmolive Company (CL) grew with the stock adding 0.25% or $0.17 to close at $68.43 on light trading volume of 3.03M compared its three months average trading volume of 3.5M. The New York New York 10022 based company operating under the Personal Products industry has been trending up for the last 52 weeks, with the shares price now 8.73% up for the period and up by 5.17% so far this year. With price target of $72.73 and a 9.7% rebound from 52-week low, Colgate-Palmolive Company has plenty of upside potential, making it a hold with a view buy.

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other similar items. It also provides pet nutrition products for everyday nutritional needs, a range of therapeutic products to manage disease conditions, and various products with natural ingredients. The company’s principal global and regional trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance. It markets and sells its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Allergan plc (AGN) had a light trading with around 3.02M shares changing hands compared to its three month average trading volume of 5.14M. The stock traded between $211.1 and $215.37 before closing at the price of $213.57 with 0.22% change on the day. The Dublin Dublin D17 E400 based company is currently trading 15.76% above its 52 week low of $184.5 and -29.12% below its 52 week high of $301.32. Both the RSI indicator and target price of  and $260.79 respectively, lead us to believe that it could rise over the coming weeks.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Conagra Brands, Inc. (CAG) saw its value increase by 0.03% as the stock gained $0.01 to finish the day at a closing price of $39.22. The stock was lighter in trading and has fluctuated between $29.76-$39.97 per share for the past year. The shares, which traded within a range of $39.18 to $39.64 during the day, are up by 6.23% in the past three months and up by 9.18% over the past six months. It is currently trading 0.48% above its 20 day moving average and 3.22% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $41.33 a share over the next twelve months. The current relative strength index (RSI) reading is 58.47.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Conagra Brands, Inc., together with its subsidiaries, operates as a food company in North America. It operates through five segments: Grocery & Snacks, Refrigerated & Frozen, International, Foodservice, and Commercial. The Grocery & Snacks segment primarily provides branded, shelf-stable food products in various retail channels in the United States. The Refrigerated & Frozen segment offers branded, temperature controlled food products in various retail channels in the United States. The International segment primarily provides branded food products, in various temperature states, in retail and foodservice channels outside of the United States. The Foodservice segment offers branded and customized food products, such as meals, entrees, prepared potatoes, sauces, and various custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The Commercial segment offers commercially branded and private label food and ingredients primarily to commercial, restaurant, foodservice, food manufacturing, and industrial customers. The company markets its products primarily under the Healthy Choice, Hunt’s, Slim Jim, Reddi-wip, Alexia, Blake’s, Frontera, Bertolli, P.F. Chang’s, and Marie Callender’s brands. The company was formerly known as ConAgra Foods, Inc. and changed its name to Conagra Brands, Inc. in November 2016. Conagra Brands, Inc. was founded in 1919 and is headquartered in Chicago, Illinois.

 

Stocks Trend Analysis: Polaris Industries Inc. (PII), Allergan plc (AGN), First Horizon National Corporation (FHN)

Polaris Industries Inc. (PII) failed to extend gains with the stock declining -1.3% or $-1.14 to close the day at $86.41 on active trading volume of 3.11M shares, compared to its three month average trading volume of 1.01M. The Medina Minnesota 55340 based company has been outperforming the recreational vehicles group over the past 52 weeks, with the stock gaining 10.29%, compared to the industry which has advanced 51.33% over the same period. With RSI of 53.88, the stock should still continue to rise and get closer to its one year target estimate of $83.31, making it a hold for now.

Polaris Industries Inc., together with its subsidiaries, designs, engineers, manufactures, and markets off-road vehicles, snowmobiles, motorcycles, and on-road vehicles in the United States, Canada, Western Europe, Australia, and Mexico. It operates through three segments: Off-Road Vehicles (ORVs)/Snowmobiles, Motorcycles, and Global Adjacent Markets. The company provides ORVs, including all-terrain vehicles and side-by-side vehicles for recreational and utility use; snowmobiles, such as independent front suspension, long travel rear suspension, hydraulic disc brakes, liquid cooling for brakes, and a three cylinder engine models; V-twin cruiser motorcycles; on-road quadri cycles and light duty commercial vehicles; and technical riding gears for the snowmobile and motorcycle industries. It also produces or supplies various replacement parts and accessories consisting of winches, bumpers/brush guards, plows, racks, mowers, tires, pull-behinds, cabs, cargo box accessories, tracks, and oils for ORVs; covers, traction products, reverse kits, electric starters, tracks, bags, windshields, oils, and lubricants for snowmobiles; and saddle bags, handlebars, backrests, exhaust, windshields, seats, oil, and various chrome accessories for motorcycles. In addition, the company sells recreational apparel, such as helmets, jackets, pants hats, goggles, gloves, boots, bibs, and leathers through a network of independent dealers and distributors, as well as through polaris.com, indianmotorcycle.com, klim.com, kolpin.com, cyclecountry.com, proarmor.com, timbersled.com, hammerheadoffroad.com, and 509films.com sites. It markets its products under the RANGER, RZR, RANGER Crew, Polaris RUSH, Victory Vision, Victory Cross Roads, Cross Country, Indian Chief Classic, Indian Chief Vintage, Indian Chieftain, Roadmaster, Scout, Scout Sixty, Victory Magnum, and Hammerhead Off-Road brand names. Polaris Industries Inc. was founded in 1954 and is headquartered in Medina, Minnesota.

Allergan plc (AGN) retreated with the stock falling -0.8% or $-1.71 to close at $213.11 on light trading volume of 3.09M compared its three months average trading volume of 5.18M. The Dublin Dublin D17 E400 based company operating under the Drugs – Generic industry has been trending down for the last 52 weeks, with the shares price now -27.99% down for the period and up by 1.48% so far this year. With price target of $260.79 and a 15.51% rebound from 52-week low, Allergan plc has plenty of upside potential, making it a hold with a view buy.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

First Horizon National Corporation (FHN) managed to rebound with the stock climbing 3.05% or $0.59 to close the day at $19.93 on higher than average trading volume of 3.08M shares, compared to its three month average trading volume of 2.26M. The Memphis Tennessee 38103 based company has been outperforming the regional – southeast banks companies by 31.1436% for last three months and its recent gains have offset losses to -0.4% YTD, versus the regional – southeast banks industry which is down -1.28% for the same period. The RSI of 53.35 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

First Horizon National Corporation operates as the bank holding company for First Tennessee Bank National Association that provides various financial services in the United States and internationally. The company offers general banking services for consumers, businesses, financial institutions, and governments. It also provides investment, financial planning, trust, asset management, and cash management services. In addition, the company is involved in fixed income securities sales, trading, and strategies for institutional clients; underwriting of bank-eligible securities and other fixed-income securities eligible for underwriting by financial subsidiaries; loan sales; derivative sales; and provision of portfolio advisory services. Further, it offers discount brokerage and full-service brokerage services; correspondent banking services; transaction processing services comprising nationwide check clearing and remittance processing services; trust, fiduciary, and agency services; credit card products; equipment finance; and investment and financial advisory services. Additionally, the company engages in mutual fund and retail insurance sales, as well as provides mortgage banking services. As of December 31, 2015, it had 185 branch locations in 8 states, including 166 branches in Tennessee; 2 branches in northwestern Georgia; 6 branches in northwestern Mississippi; 7 branches in North Carolina; and 1 branch each in Virginia, South Carolina, Florida, and Texas. The company was founded in 1968 and is headquartered in Memphis, Tennessee.

 

Stocks Roundup: Helios and Matheson Analytics Inc. (HMNY), Prologis, Inc. (PLD), Allergan plc (AGN)

Helios and Matheson Analytics Inc. (HMNY) grew with the stock adding 14.16% or $0.49 to close at $3.95 on light trading volume of 3.84M compared its three months average trading volume of 477.73K. The New York New York 10118 based company operating under the Information Technology Services industry has been trending up for the last 52 weeks, with the shares price now 153.21% up for the period and up by 19.7% so far this year. With price target of $0 and a 283.5% rebound from 52-week low, Helios and Matheson Analytics Inc. has plenty of upside potential, making it a hold with a view buy.

Helios and Matheson Analytics Inc. provides a range of information technology (IT) consulting solutions, custom application development, and analytics services to Fortune 1000 companies and other organizations in the United States. Its services include application value management, application development, integration, independent validation, infrastructure, information management, and analytics services. The company supports various computer technology platforms and client IT projects using a range of third-party software applications. Its clients operate in various industries, including banking, financial services, insurance, and healthcare. The company was formerly known as Helios and Matheson Information Technology Inc. and changed its name to Helios and Matheson Analytics Inc. in May 2013. The company was founded in 1982 and is headquartered in New York, New York. Helios and Matheson Analytics Inc. is a subsidiary of Helios and Matheson Information Technology Ltd.

Prologis, Inc. (PLD) had a active trading with around 3.83M shares changing hands compared to its three month average trading volume of 2.79M. The stock traded between $52.34 and $52.85 before closing at the price of $52.83 with 0.49% change on the day. The San Francisco California 94111 based company is currently trading 55.19% above its 52 week low of $35.25 and -2.79% below its 52 week high of $54.87. Both the RSI indicator and target price of  and $15.46 respectively, lead us to believe that it could rise over the coming weeks.

Prologis Inc. is an independent equity real estate investment trust. It invests in the real estate markets across the globe. The firm engages in the ownership, development, management, and leasing of industrial distribution and retail properties. It was previously known as Security Capital Investment Trust. Prologis Inc. was formed in 1991 and is based in San Francisco, California with an additional office in Denver, Colorado.

Allergan plc (AGN) saw its value increase by 0.22% as the stock gained $0.48 to finish the day at a closing price of $214.82. The stock was lighter in trading and has fluctuated between $184.5-$301.32 per share for the past year. The shares, which traded within a range of $211.11 to $218.08 during the day, are down by -7.83% in the past three months and down by -13.72% over the past six months. It is currently trading 1.55% above its 20 day moving average and 6.66% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $260.79 a share over the next twelve months. The current relative strength index (RSI) reading is 62.15.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.